Switching from Ozempic to Wegovy for Weight Loss

Are Ozempic and Wegovy the same medicine, and if so, why does it matter which one you're on?

They share an active ingredient: semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. In that sense, yes, the same molecule is doing the work. But licensed medicines aren't just molecules. The licence covers the indication, the approved dose range, the evidence base, and the clinical population the trial studied. Ozempic is licensed in the UK for type 2 diabetes management, the doses top out at 1mg weekly (2mg in some presentations). Wegovy, by contrast, is licensed specifically for weight management in adults, and its dose pathway runs up to 2.4mg weekly, with a 7.2mg maintenance dose now also approved by the MHRA as of April 2026.

That higher dose ceiling matters. The weight-loss evidence for semaglutide was built at 2.4mg, in trials like STEP 1, 68 weeks, showing around 15% average body-weight reduction at the licensed maintenance dose, as published in the New England Journal of Medicine. Ozempic's 1mg dose was never studied for weight management at that scale. So switching from Ozempic to Wegovy isn't simply a brand swap; it's moving to a different dose schedule under a different licence, for a different clinical purpose. Worth checking that your prescriber is across both.

Does it matter that Ozempic isn't licensed for weight loss in the UK?

Practically speaking, it matters more than people expect. When the MHRA licenses a medicine, it sets out the exact population, dose and condition for which the evidence was assessed. Using Ozempic off-label for weight loss means the prescriber is working outside that evidence base, and, importantly, at a lower dose than the one that produced the weight-loss results in clinical trials. The NHS medicines page for semaglutide is explicit that Wegovy and Ozempic are different products for different purposes.

There's also a practical supply dimension. NHS shortages of Ozempic have persisted in part because of demand from people using it outside its diabetes licence. The MHRA and NHS England have both flagged this publicly. For someone whose goal is weight management, the licensed product (Wegovy) is the appropriate route, and it means your treatment sits on a foundation of regulated, purpose-built evidence. If you've been on Ozempic and your weight loss has stalled, that dose ceiling may be part of the picture.

The comparison below sets out the key factual differences.

What does switching from Ozempic to Wegovy actually involve?

The mechanics are straightforward in principle: Wegovy has its own titration schedule (starting at 0.25mg weekly, stepping up over roughly 16–20 weeks to the maintenance dose), and a prescriber will decide where in that schedule to place you based on your current dose, tolerance history and clinical picture. There is no self-directed equivalent of carrying your Ozempic dose across to Wegovy.

What switching ozempic to wegovy does NOT look like is logging onto a website, selecting a strength and clicking pay. These are prescription-only medicines. A prescriber needs to see your current treatment, your reason for switching, and your full health picture before writing a new prescription. At nume, transfer patients are asked to provide evidence of current treatment as part of the consultation, our prescribers review that before anything is issued. You can read more about how the consultation works on our Wegovy treatment page.

One thing patients sometimes ask: can you just start Wegovy at the dose you were reaching on Ozempic? The titration schedule exists for a reason, the gastrointestinal side effects of semaglutide are dose-related, and the step-up exists to let your system adjust. Whether you start at 0.25mg or further along the schedule is a clinical call, not a personal preference. Our prescribers handle this on a case-by-case basis; if you have a question before you start, our team is reachable through our contact page.

If Ozempic isn't the right route, what is licensed for weight loss in the UK?

Two injectable medicines are currently licensed in the UK for weight management in adults: Wegovy (semaglutide, by Novo Nordisk) and Mounjaro (tirzepatide, by Eli Lilly). You can compare them in detail on our Wegovy vs Ozempic page, or explore the broader landscape of weight-loss treatment options we support.

Mounjaro is a dual GIP and GLP-1 receptor agonist, the only medicine of its kind licensed in the UK. In the SURMOUNT-5 head-to-head trial (72 weeks, adults with obesity, no diabetes), tirzepatide produced greater average weight reduction than semaglutide 2.4mg. Wegovy's new 7.2mg dose narrows that gap. Which is more appropriate depends on your health history, any other medicines you take, and your prescriber's assessment, it isn't a ranking.

People switching from other treatments, including from injectable semaglutide to something else entirely, can find relevant guidance on our switching to Wegovy page, or if you're coming from Saxenda, the Saxenda-to-Wegovy page covers that specific transition. If you've been using Mounjaro and are considering a change, our page on switching from Mounjaro to Wegovy walks through what that process involves. The common thread: every switch goes through a prescriber, and the clinical review happens before any medicine is dispatched.

For weight management, the right starting point is a consultation. Our prescribers review your answers the same day, if you submit before midday on a weekday, treatment can be dispatched the same afternoon and arrive with DPD the next working morning. Start your free consultation and let a clinician work through the options with you.